Top Industry Leaders in the Plasma Therapy Market
Latest Plasma Therapy Companies Update:
Octapharma
January 22, 2024: Published data from the WIL-31 study, marking a milestone in improving long-term care for severe von Willebrand disease (VWD) patients.January 9, 2024: Announced availability of Balfaxar® for warfarin reversal in urgent surgery and invasive procedures.
CSL (Australia)
April 2023: Received FDA approval for a new prefilled syringe of Hizentra for patients with primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIPD).
Grifols (Spain)
March 2022 Received European approvals for XEMBIFY, a 20% subcutaneous immunoglobulin (SCIG) for PI treatment.
List of Plasma Therapy Key companies in the market
- BioLife Plasma Services (US)
- Cambryn Biologics LLC (US)
- Biotest (Germany)
- CSL Ltd. (Australia)
- Grifols International S.A. (Spain)
- Kedrion S.p.A. (Italy)
- LFB S.A (France)
- Bio Products Laboratory Ltd. (U.K.)
- China Biologic Products, Inc. (China)
- Octapharma (Switzerland)
- Arthrex, Inc. (US)
- DePuy Synthes Companies (US)
- Grifols S.A (Spain)
- Global Stem Cells Group, Inc. (US)
- Juventix Regenerative Medical LLC (U.S.)
- Celling Biosciences, Inc. (U.S.)